Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CDCA3 pseudogene 1 (CDCA3P1) is a non-protein-coding genomic locus annotated as a pseudogene of CDCA3, located in the human genome. It produces a long non-coding RNA transcript but does not encode a functional protein. Unlike its parent gene CDCA3 (cell division cycle-associated protein 3), which has critical cell cycle regulatory roles and documented involvement in cancer biology, the pseudogene CDCA3P1 has no documented function as a therapeutic target, enzyme, transporter, or receptor. There is no current evidence in the literature to suggest that CDCA3P1 is a relevant molecular target for drug discovery, nor is it implicated as a biomarker or involved in disease. Its status as a pseudogene indicates it is likely non-functional, though like other lncRNAs or pseudogenes, potential regulatory functions are theoretically possible but not currently demonstrated for this specific locus. Key clarifications: - CDCA3P1 is not a therapeutic target and has no established function; it is a pseudogene, not a protein, enzyme, transporter, or signaling molecule. - There may be confusion in literature searches between CDCA3 (a functional cell cycle protein and recognized cancer biomarker/target) and CDCA3P1 (the unrelated noncoding pseudogene). - Databases such as HGNC and NCBI confirm the status of CDCA3P1 as a pseudogene with no functional annotation. In summary: CDCA3P1 is a noncoding pseudogene transcript with no evidence of protein-coding function, biological role, or therapeutic relevance. If you are searching for a cancer target, the intended molecule may be CDCA3 (cell division cycle-associated protein 3), not CDCA3P1.
None reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CDCA3 pseudogene 1 (CDCA3P1).